HIKAL · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 22/100 — Quality 31 · Momentum 0
| Share price | ₹227.26 |
| Market cap | ₹3,018 Cr |
| P/B ratio | 2.5 |
| ROCE | -1.0% |
| Dividend yield | 0.41% |
| Book value | ₹97.40 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,713 Cr | ₹-49 Cr | 13.0% |
| 2025 | ₹1,860 Cr | ₹91 Cr | 18.0% |
| 2024 | ₹1,785 Cr | ₹70 Cr | 15.0% |
| 2023 | ₹2,023 Cr | ₹78 Cr | 13.0% |
| 2022 | ₹1,943 Cr | ₹160 Cr | 18.0% |
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers s